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EARLY DETECTION OF CARDIOTOXICITY

Current approach
Periodic assessment for LVEF is the most widely used non-invasive method for detecting cardiotoxicity LVEF either via echocardiography or multigated acquisition scanning. Although several available guidelines exist none specify how often, by what means or how long cardiac function should be monitored during and after cancer treatment. The recommendations of these guidelines are not consistent and seem to be based on modest evidence. (5) Though LVEF is a crude index of cardiac function, it is relatively insensitive in detecting anticancer drug-induced cardiotoxicity at an early stage. Usually there are compensatory mechanisms in place to ensure normal overall function in a patient despite an initial reduction in myocardial contractility. As a rule no considerable
INTRODUCTION
Anticancer therapy can frequently result in serious side effects on specific organs and cardiac toxicity is of considerable concern.
Once toxicity develops it may compromise the treatment's clinical effectiveness independent of the oncologic prognosis.
( Over the last years, the weight of the cardiac toxicity of anticancer treatment has markedly increased due to an improvement in patient survival; an ageing population; the tendency to use progressively higher doses of anthracyclines; the introduction of new anticancer drugs with unexpected cardiac toxicity; and combined treatments with synergistic harmful effects on the heart. (2, 3) According to American cardiologic guidelines, patients receiving anticancer treatment may at present be considered a Stage A heart failure group, namely those with an increased risk of developing LVD. (4) Avoiding cardiotoxicity has therefore become a primary Once LVD develops, complete recovery of cardiac function occurs in only 42% of patients, despite optimal pharmacologic therapy. (6) The diagnosis of cardiotoxicity evidenced by a decrease in LVEF therefore precludes any chance of preventing its development. (5, (7) (8) (9) Measuring LVEF also presents a number of challenges with regards to image quality, assumption of left ventricular geometry, load dependency and expertise. (10) Improved accuracy and reproducibility of LVEF measurements is an actual need in patients receiving anticancer therapy, since clinical decision making relies completely on these measurements. Multiple gated acquisition (MUGA) scan can reduce inter-observer variability with the disadvantages of including the exposure to radioactivity and limited information that can be obtained on cardiac structure and diastolic function.
Magnetic resonance imaging (MRI) is considered the gold standard for the evaluation of cardiac volumes, mass, and both systolic and diastolic function. (5) However, high cost and the lack of availability limit the routine use of MRI.
These limitations have prompted investigations into the development of more sophisticated echocardiographic techniques, like contrast echocardiography and real-time 3D-echocardiography, which allow for an improvement in the accuracy of calculating LVEF. (10, 11) Both Doppler tissue imaging and speckle-tracking echocardiography appear to be more sensitive than standard echocardiography in detecting subclinical changes in cardiac performance that anticipate a decrease in conventional LVEF, even if long-term data on large populations, confirming the clinical relevance of such changes, are not available yet. (10, 11) The role of biomarkers A novel approach based on the use of cardiac biomarkers has emerged in the last decade, resulting in a cost-effective diagnostic tool for early, real time identification, assessment and monitoring of anticancer drug-induced cardiotoxicity. This approach seems to overcome most of the limitations of the techniques described above, as it has proven to be more sensitive and more specific, cheaper, repeatable without damage for the patients, readily available even in small hospitals, and without inter-observer variability.
Troponins
Troponin (Tn) is considered the gold standard biomarker for myocardial injury from any cause. (12) The employment of cardiac troponins as biomarkers of early chemotherapy-induced cardiotoxicity was initially reported in animal models. (13) Moving to the clinical field, Lipshultz, et al. (14) reported that, in children treated with anthracyclines (AC) for lymphoblastic leukaemia, a TnT increase in about 30% of cases, sometimes persisting for months, suggesting that cardiac damage, elicited by AC, may last for a long time. This increase positively correlated with AC dose and predicted morbidity and mortality.
More recently, in the same population, followed-up for 5 years after treatment, the authors observed that children who had experienced at least one raise in TnT during treatment showed late cardiac abnormalities at echocardiography. (15) Further studies have demonstrated that TnI is also a sensitive and specific marker for myocardial injury in adults treated with high-dose chemotherapy (CT), and is able to predict, at a very early phase, both development and severity of future LVD ( Figure 1 ). (16) (17) (18) Additionally, in 703 Patients showing an increase of TnI during trastuzumab treatment had a three-fold lower chance of recovery from cardiac dysfunction and had a higher incidence of cardiac events ( showing only a transient increase in this marker. (19) Troponin measurements have proven to be useful for the early detection of cardiotoxicity also in patients treated with a standard dose of CT. Auner, et al. (20) reported a TnT increase in 15% of patients treated with standard doses of AC. Patients with an elevated TnT level showed a significantly greater absolute decrease in LVEF than those without an elevation in the marker (10% vs. 2%; p= 0.017). A significant LVEF reduction was observed in TnI positive patients treated with AC for leukemia. (21) In addition, an increased
TnT level, detected in the first 3-5 days following administration of standard doses of AC, predicted diastolic dysfunction in 34% of patients. (22) Troponins may also be utilised for the early detection of cardiac injury in patients undergoing treatment with new targeted anti- from cardiotoxicity -despite optimised heart failure treatmentthus possibly distinguishing between reversible and irreversible cardiac injury. In a recent study, the timing of maximum detectable
TnI value preceded maximum decline in LVEF in patients receiving both trastuzumab and lapatinib -a tyrosine-kinase inhibitorfollowing AC-based CT. (24) In 86 patients with metastatic renal cancer treated with tyrosine-kinase inhibitor sunitinib or sorafenib and monitored prospectively with serial TnT measurements an increase in the markers was observed in 10% of patients. Ninety percent of them showed a decrease in LVEF or regional contraction abnormalities. (25) These data suggest that troponins may be useful for assessing cardiotoxicity in patients treated with both old and new antineoplastic treatments. Possibly, the release of troponin reflects a final common event for multiple cardiotoxic mechanisms.
As many non-ischaemic pathophysiological conditions can cause myocardial necrosis, and therefore elevations in cardiac troponin concentrations (Table 2 ), other possible causes of troponin increase must obviously to be excluded. (26) Different timing of troponins increase panel A). (17) Conversely, in breast cancer patients treated with trastuzumab, we found that the first increase in troponin was most frequent soon after the first cycle of trastuzumab and occurred only in patients previously treated with AC ( Figure 3 ; panel B), suggesting a possible combined mechanism: TnI rise in these patients possibly reflects AC injury facilitated by trastuzumab, rather than a de-novo cardiac damage.
(23) This hypothesis might explain the different timing of the rise in TnI in our studies. Many studies have also elucidated that troponin value can remain elevated for a period ranging from a few hours to several months, after the completion of CT. (19, 20, 21, 28, 30) On the other hand, the exact time-point at which a negative troponin value reaches 100% of specificity for no further troponin release cannot yet be defined, (31) therefore, repeated blood samples are required to pick out a possible troponin increase. This represents a possible limitation for using these markers in clinical practice. However, this strategy seems to be justified and absolutely cost-effective when negative values allow for the exclusion of most patients from a long-term monitoring programme with an expensive imaging technique. 
High-sensitivity troponins
Recently the technological evolution led to the generation of troponin assays with improved sensitivity, enabling a reliable detection of very low amounts of troponin. These assays are referred as "high sensitivity" troponins although definite criteria to define their analytical performance are still lacking. These tests could be of particular interest in the cardiotoxicity field, and may offer some advantages, as often we are dealing with a very low concentration of troponin, and it is of utmost importance to use systems showing high precision also at a very low level. (32) The possible employment of high-sensitivity (HS) troponins in this setting is provided by a recent multicentre study, in which the authors evaluated global and regional myocardial function by tissue Doppler and strain rate imaging, combined with HS TnI, at baseline, and 3 and 6 months during CT including AC and trastuzumab. (Table 3) . In most of the studies an association between increased levels of NP and LVD was found. However, only few reports indicated NP as predictors of LVD after anticancer treatment. We conducted a retrospective study including 52
patients receiving high-dose chemotherapy for aggressive malignancies. (39) Three distinct increase patterns were found, according to the NT-proBNP trend during the 6 blood samples taken in the 
Other proposed biomarkers
Other molecules have been proposed as biomarkers for cardiovascular injury related to CT-induced toxic effect.
New markers of myocardial ischaemia and necrosis such as fatty acid binding protein and glycogen phosphorylase isoenzyme BB (brain) have been reported to also increase after CT with AC. (56, 57) However, although these markers are highly sensitive, they have relatively low cardiac specificity and available data are insufficient to propose their use in the follow-up of oncology patients.
The increase of markers of inflammation, such as cytokines, has also been described after CT. Mercuro, et al. (58) 
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Lipshultz, et al. (55) Higher NT-proBNP levels are associated with diastolic abnormalities ANP and BNP early increase after CT BNP predicted development of CHF NT-proBNP increased in patients with ventricular dysfunction BNP elevated in patients with late cardiac dysfunction BNP levels are sensitive indicator of myocardial injury NT-proBNP is a marker of acute toxicity NT-proBNP concentrations correlate with systolic and diastolic dysfunction NT-proBNP doesn't predict cardiac dysfunction NT-proBNP is a sensitive marker for the early detection of the course-to-course effects of CT NT-proBNP levels are signifi cantly related to LVEDD increase Higher NT-proBNP levels are associated with reduced LVEF NT-pro BNP increase was predictive of LV impairment Persistently elevated NT-pro BNP identifi es high risk patients NT-proBNP correlated with increased LVESD and LVEDD NT-proBNP correlated with LV thickness-to-dimension ratio based CT for testicular cancer many years before. In a similar population Vaughn, et al. (61) reported that long-term cancer survivors treated with CT showed increased markers of endothelial injury compared to CT-naive survivors. These findings suggest that CT may induce endothelial dysfunction and accelerate atherosclerotic processes, leading to an increased risk for future cardiovascular diseases. (62) However, at present, no correlation with long-term cardiovascular events has been demonstrated, and the predictive role of these markers has yet to be defined.
PREVENTION OF CARDIOTOXICITY
Current possible strategies
To prevent cardiotoxicity, several preventive measures are currently used, including limitation of cumulative AC dose, slowing down of AC administration, and use of less cardiotoxic AC analogues.
However, the addition of cardioprotectants or nutritional supplements and detection of early signs of cardiotoxicity by biomarkers are the two most promising strategies. (11, 63, 64) Addition of cardioprotectants to AC treatment
Carvedilol, a beta-blocker with alfa-1-blocking vasodilatory properties, has also showed strong antioxidant activity that lends it a cardioprotective effect against doxorubicin. (63) This favourable effect was confirmed in an in-vitro study (65) and in a randomised study in which prophylactic use of carvedilol prevented LVD and reduced mortality in a small population of patients treated with AC. (66) Dexrazoxane, an iron-chelating agent, significantly reduced ACrelated cardiotoxicity in adults with different solid tumours and in children with acute lymphoblastic leukaemia and Ewing's sarcoma. (15, 67, 68) Moreover, the same agent was more effective than an AC prolonged infusion in preventing cardiotoxicity in 23
Ewing's sarcoma patients treated with doxorubicin. (Table 4) . Although preliminary findings show that all these agents may have cardioprotective effects their utility in preventing CMP need to be confirmed by further investigation. (3, 11, 63, 67) The role of biomarkers in the prevention of cardiotoxicity A pharmacologic preventive approach extended to all cancer patients treated with CT has a high cost-benefit ratio and exposes patients to possible side effects, including a potential antagonistic effect to antitumor activity of the treatment also in patients less A recent prospective study reported that valsartan, an angiotensin II receptor blocker, given at the same time as doxorubicin was able to prevent an increase in atrial natriuretic peptide, BNP, and left ventricular diastolic diameter and prolongation and dispersion in QTc interval in patients with non-Hodgkin's lymphoma. (72) Lipshultz, et al. (68) reported that TnT elevation occurred significantly more frequently in leukaemic children receiving doxorubicin alone than in those in whose doxorubicin was administered in association with dexrazoxane (50% vs. 21%, respectively; p<0.001).
The usefulness of TnI screening for a selection of patients requiring prophylactic cardioprotective therapy was investigated in a randomised, controlled trial carried out at our institute. (30) The cardioprotective effects of enalapril were evaluated in 413 patients treated with high-dose AC. The 114 (24%) patients showing early
TnI increase were randomised to enalapril or no treatment.
Enalapril was initiated 1 month after the completion of CT, titrated at the maximal tolerated dose, and continued for 1 year. In the enalapril-treated group, LVEF did not change during the follow-up period. Conversely, in patients not receiving enalapril a progressive reduction in LVEF and an increase in end-diastolic and endsystolic volumes were observed (Table 5 ). Moreover, a significantly lower incidence of adverse cardiac events was found in enalapriltreated patients than in controls at a 1-year follow-up (2% vs.52%; p<0.001). (30) Going from clinical research to the real world we applied this strategy to our daily clinical practice. A treatment with enalapril is usually started in all patients showing a TnI increase after treatment with both old and new anticancer drugs. In more than 1 350 treated patients no case of significant reduction in LVEF (below 50%) was observed during a mean follow-up of 4.6 years (unpublished data).
These results confirm that this targeted prophylactic approach can be really effective in preventing cardiotoxicity and may be easily and safely applied in daily clinical practice. 
TREATMENT OF CARDIOTOXICITY
Anthracyclines-induced cardiotoxicity
Historically, AC-induced cardiomyopathy (CMP) was believed to be refractory to conventional therapy. This opinion was however based either on findings reported in old studies, in which standard therapy included only the use of digoxin and diuretics, or in studies with very small sample sizes. In a recent study, the response to modern HF therapy, including ACEI and BB has been prospectively evaluated in 201 patients with AC-induced CMP. (6) In this study the time elapsed from the end of CT to the start of HF therapy (time-to-treatment) including ACEI 
Trastuzumab-induced cardiotoxicity
The incorporation of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2, to the standard regimens for treatment of breast cancer that over-expresses HER2
receptors -a variant of the disease generally associated with a poor prognosis -has led to a major improvement in outcome. (75) Its use however has resulted in an unexpectedly high rate of cardiotoxicity which occurs in up to 7% of patients when used as monotherapy and in 28% of patients when associated with AC.
Trastuzumab causes a different form of cardiotoxicity from that typical of AC: It is not dose-dependent; AC-typical ultra structural changes are not seen on cardiac biopsy specimens; and it is not caused by oxidative mechanisms. Whether trastuzumab-related LVD has a course that is modified with ACEI and BB is still uncertain. (77) Follow-up data from large trials show that in many patients treated with anthracycline and sequentially with trastuzumab LVD does and, when tolerated, BB was a critical variable for recovery from LVD. Indeed, a strong inverse relationship between time-totreatment and LVEF improvement in response to HF therapy was observed (R = -0.66; p<0.001). In particular, the likelihood of obtaining a complete LVEF recovery was higher in patients in whom HF treatment was initiated because of LVD detection within 2 months after the end of CT. After this time limit the percentage of complete LVD recovery progressively decreased and only partial recovery was observed after 6 months. When LVD was detected after 12 months the possibility of obtaining at least a partial recovery was completely exhausted ( Figure 5 ). Notably patients showing complete LVD recovery had a significantly lower rate of adverse cardiac events than those who did not recover (5% vs. 30%).
Moreover complete recovery was more frequently observed in patients with asymptomatic LVD than in those with symptoms of HF (56% vs. 11%; p<0.001). (6) The monitoring of cardiotoxicity based exclusively on symptoms evaluation may therefore hinder the opportunity to detect LVD early in a still asymptomatic and reversible stage. It is also likely that in most previously published studies the poor response to HF therapy was due to undertreatment with ACEI and BB and to late beginning of HF therapy (in most cases it was started more than 12 months after the end of chemotherapy) when LVD has been shown to be no longer reversible. This underlines that an early detection of cardiotoxicity is of pivotal importance and that a prompt therapy based on the association of ACEI and BB should always be considered and undertaken in all cases of anthracycline-induced CMP. Conflict of interest: none declared.
not recover; that up to two-thirds of patients continue to receive cardiac medications after complete functional recovery; and that many patients show a LVEF lower than baseline despite optimal HF therapy. (78) For these reasons some uncertainties on resuming trastuzumab after cardiac function recovery still exist. This is particularly true for patients treated with curative intent while the risk of developing cardiac impairment in the metastatic setting is largely counterbalanced by the benefit of trastuzumab.
CONCLUSION
At present, anticancer treatment-induced cardiotoxicity still remains a serious problem strongly impacting both quality of life and over- 
